Century Therapeutics Regains Nasdaq Compliance, Opts Against Approved Reverse Stock Split

summarizeSummary

Century Therapeutics announced that its stockholders approved a reverse stock split, but the company will not implement it after regaining compliance with Nasdaq's minimum bid price requirement.

check_boxKey Events

• Stockholders Approve Reverse Stock Split

  At a special meeting on January 22, 2026, stockholders approved an amendment to the company's charter to effect a reverse stock split at a ratio between 1-for-5 and 1-for-30, subject to Board discretion.

• Regains Nasdaq Compliance

  On January 22, 2026, Century Therapeutics received a letter from Nasdaq confirming it has regained compliance with the minimum closing bid price rule ($1.00 per share) and all other listing standards.

• Reverse Split Will Not Be Implemented

  As a direct result of regaining Nasdaq compliance, the company announced it does not intend to effect the reverse stock split, despite stockholder approval.

auto_awesomeAnalysis

Century Therapeutics' announcement that it has regained compliance with Nasdaq's minimum bid price rule is a significant positive development. This removes the immediate threat of delisting and, crucially, allows the company to avoid implementing a reverse stock split, which was approved by shareholders as a contingency. Reverse splits are often viewed negatively by the market as they can signal underlying issues or lead to reduced liquidity. By resolving the compliance issue without resorting to this measure, the company removes a potential overhang and may improve investor sentiment. This follows a recent significant capital raise, suggesting the company is stabilizing its financial and listing position.